Latest News and Press Releases
Want to stay updated on the latest news?
-
NRTX-1001 administration has been well-tolerated in all individuals treated to date 4 of 5 subjects treated with the lower dose of NRTX-1001 report >50% seizure reduction 3 of 5 subjects report...
-
Neurona Therapeutics to present updated clinical data from NRTX-1001 investigational cell therapy program at AAN Annual Meeting
-
SAN FRANCISCO, April 01, 2022 (GLOBE NEWSWIRE) -- Neurona Therapeutics, a clinical-stage biotherapeutics company advancing regenerative cell therapies for the treatment of neurological disorders,...